Nordic Capital, one of Europe’s most active private equity firms this year, agreed to invest 450 million euros ($535 million) in Danish dermatology firm LEO Pharma A/S.
The investment firm is buying a minority stake in LEO Pharma, according to a statement Tuesday, which didn’t disclose financial terms. The deal values LEO Pharma at about 3 billion euros including debt, people familiar with the matter said, asking not to be identified discussion confidential information.
LEO Pharma, a maker of topical medication for skin conditions, has been looking for a new investor since last year with the help of its advisers at Moelis & Co. The LEO Foundation will remain the majority shareholder of the company, according to the statement. A representative for Nordic Capital declined to comment on the valuation of the deal.
By Jan-Henrik Foerster
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.